Employees Retirement System of Texas Has $2.32 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Employees Retirement System of Texas reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 27.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,042 shares of the biopharmaceutical company's stock after selling 15,560 shares during the period. Employees Retirement System of Texas' holdings in Bristol-Myers Squibb were worth $2,321,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. United Bank increased its holdings in shares of Bristol-Myers Squibb by 2.7% in the third quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock valued at $896,000 after buying an additional 456 shares in the last quarter. Morse Asset Management Inc lifted its holdings in shares of Bristol-Myers Squibb by 25.0% during the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after purchasing an additional 2,000 shares during the last quarter. EP Wealth Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 25.0% in the 3rd quarter. EP Wealth Advisors LLC now owns 49,252 shares of the biopharmaceutical company's stock valued at $2,548,000 after purchasing an additional 9,836 shares during the period. Dunhill Financial LLC increased its stake in Bristol-Myers Squibb by 39.8% in the 3rd quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 189 shares in the last quarter. Finally, MML Investors Services LLC raised its holdings in Bristol-Myers Squibb by 1.5% during the 3rd quarter. MML Investors Services LLC now owns 313,688 shares of the biopharmaceutical company's stock worth $16,230,000 after buying an additional 4,554 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

BMY has been the topic of several analyst reports. Citigroup lifted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Truist Financial raised their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. UBS Group dropped their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday. Finally, Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and raised their price objective for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $57.67.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded up $0.22 during trading on Friday, reaching $50.68. The stock had a trading volume of 13,408,290 shares, compared to its average volume of 12,926,949. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a fifty day simple moving average of $57.71 and a two-hundred day simple moving average of $56.78. The firm has a market capitalization of $103.11 billion, a price-to-earnings ratio of -11.46, a P/E/G ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.89%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,823 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.